Effect of cimetidine on an oral single-dose mefloquine pharmacokinetics in humans

Asia Pacific Journal of Pharmacology

Volumn 12, Issue 1-2, 1997, Pages 51-55

  Sunbhanich, M ^a   Ridtitid, W ^a   Wongnawa, M ^a   Akesiripong, S ^b   Chamnongchob, P ^c  

^a Faculty of Science   (Thailand)

^b PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^c MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

Cimetidine; Drug interaction; Mefloquine; Pharmacokinetics

Indexed keywords

CIMETIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; MEFLOQUINE;

ADULT; AREA UNDER THE CURVE; BIOAVAILABILITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION;

EID: 0030821939     PISSN: 02179687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. 2-receptor antagonists: Clinical pharmacokinetics and drug interaction potential. Clinical Pharmacokinetics 1988; 15: 205-15.
2. 2-receptor antagonists. Medical Toxicology 1986; 1: 192-216.
3. Lauritsen K, Laursen LS, Rask-Madsen, J. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part I). Clinical Pharmacokinetics 1990; 19: 11-31.
4. 2-receptor antagonists on drug interaction in rats Drug Metabolism and Disposition 1986, 14: 649-53
5. Somogyi A, Muirhead M. Pharmacokinetic interactions of cimetidine. Clinical Pharmacokinetics 1987; 12: 321-66.
6. Lewis JH. Hepatic effects of drugs used in the treatment of peptic ulcer disease. American Journal of Gastroenterology 1987; 82. 987-1003.
7. Reynolds JC. The clinical importance of drug interactions with antiulcer therapy Journal of Clinical Gastroenterology 1990; 12 (Suppl. 2): S54-63.
8. Gugler R, Jenson JC. Interaction between cimetidine and metronidazole. New England Journal of Medicine 1984; 309: 1518-9.
9. Reilly PEB, Winzor DJ. Adverse drug interactions with cimetidine: competitive inhibition of mono-oxygenase-dependent N-demethylation of morphine. Biochemical Pharmacology 1984; 33: 1151-3.
10. Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine: clinical implications. Clinical Pharmacokinetics 1996; 30: 263-99.
11. Wanwimolruk S, Sunbhanich M, Pongmarutai M, Patamasucon P. Effect of cimetidine and ranitidine on the pharmacokinetics of quinine. British Journal of Clinical Pharmacology 1986; 22: 346-50.
12. Karbwang J, White NJ. Clinical pharmacokinetics of mefloquine. Clinical Pharmacokinetics 1990; 19: 264-79.
13. Na-Bangchang K, Molunto P, Banmairuroi V, Thanavibul A, Karbwang J. Pharmacokinetics of mefloquine when given as a single and two divided-dose regimens. International Journal of Clinical Pharmacology Research 1995; 15: 215-20.
14. White NJ. Antimalarial drug resistance: the pace quickens. Journal of Antimicrobial Chemotherapy 1992; 30: 571-85.
15. Edstein MD, Lika ID, Chonguphajaisiddhi T, Sabchareon A, Webster HK. Quantitation of Fansimef components (mefloquine + sulfadoxine + pyrimethamine) in human plasma by two high-performance liquid Chromatographic methods. Therapeutic Drug Monitoring 1991; 13: 146-51.
16. Metzler CM, Weiner DL. PCNONLIN user's guide (computer program). Lexington: Statistical Consultants Inc., 1984.
17. Desjardins RE, Pamplin CL, Von Bredow J, Barry KG, Canfield CJ. Kinetics of a new antimalarial, mefloquine. Clinical Pharmacology and Therapeutics 1979; 26: 372-9.
18. Franssen G, Rouveix B, Lebras J, Bauchet J, Verdier F, Michon C, Bricaire F. Divided-dose kinetics of mefloquine in man. British Journal of Clinical Pharmacology 1989; 28: 179-84.
19. Juma FD, Ogeto JO. Mefloquine disposition in normals and in patients with severe Plasmodium falciparum malaria. European Journal of Drug Metabolism and Pharmacokinetics 1989; 14: 15-8.
20. Karbwang J, Bunnag D, Breckenridge AM, Back DJ. The pharmacokinetics of mefloquine when given alone or in combination with sulfadoxine and pyrimethamine in Thai male and female subjects. European Journal of Clinical Pharmacology 1987; 32: 173-7.
21. Karbwang J, Looareesuwan S, Back DJ, Migasena S, Bunnag D, et al. Effect of oral contraceptive steroids on the clinical cause of malaria infection and on the pharmacokinetics of mefloquine in Thai women. Bulletin of the World Health Organization 1988; 66: 763-7.
22. Riviere JH, Back DJ, Breckenridge AM, Howells RE. The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism. British Journal of Clinical Pharmacology 1985; 20: 469-74.
23. Gonzalez FJ, Idle JR. Pharmacogenetic phenotyping and genotyping. Clinical Pharmacokinetics 1994; 26: 59-70.
24. Spinier SA, Cheng JWM, Kindwall KE. Possible inhibition of hepatic metabolism of quinidine by erythromycin. Clinical Pharmacology and Therapeutics 1995; 57: 89-94.
25. Suebsang L, Werndorfer WH, Rooney W. Sensitivity to quinine and mefloquine of Plasmodium falciparum in Thailand. Bulletin of the World Health Organization 1986; 6: 169-78.